Purpose: Optical coherence tomography (OCT) is of interest to visualize microscopic esophageal tumor extensions to improve tumor delineation for radiation therapy (RT) planning. Fiducial marker placement is a common method to ensure target localization during planning and treatment. Visualization of these fiducial markers on OCT permits integrating OCT and computed tomography (CT) images used for RT planning via image registration. We studied the visibility of 13 (eight types) commercially available solid and liquid fiducial markers in OCT images at different depths using dedicated esophageal phantoms and evaluated marker placement depth in clinical practice. Materials and Methods: We designed and fabricated dedicated esophageal phantoms, in which three layers mimic the anatomical wall structures of a healthy human esophagus. We successfully implanted 13 commercially available fiducial markers that varied in diameter and material property at depths between 0.5 and 3.0 mm. The resulting esophageal phantoms were imaged with OCT, and marker visibility was assessed qualitatively and quantitatively using the contrast-to-background-noise ratio (CNR). The CNR was defined as the difference between the mean intensity of the fiducial markers and the mean intensity of the background divided by the standard deviation of the background intensity. To determine whether, in current clinical practice, the implanted fiducial markers are within the OCT visualization range (up to 3.0 mm depth), we retrospectively measured the distance of 19 fiducial markers to the esophageal lumen on CT scans of 16 esophageal cancer patients. Results: In the esophageal phantoms, all the included fiducial markers were visible on OCT at all investigated depths. Solid fiducial markers were better visible on OCT than liquid fiducial markers Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is noncommercial and no modifications or adaptations are made.
INTRODUCTION
Radiation therapy (RT) with concurrent chemotherapy in esophageal cancer patients is either applied preoperatively in an operable disease stage or as a part of definitive treatment in inoperable or unresectable cases. 1 In the treatment of esophageal cancer with RT, it is still a challenge to deliver the radiation dose accurately to the tumor and tumor-involved lymph nodes while sparing the radiosensitive surrounding healthy tissues. Computed tomography (CT) is the standard imaging technique used for RT planning and tumor extent delineation is a crucial step in the treatment planning process. Esophageal tumor delineation on CT is, however, difficult due to poor visibility of the tumor extension and lack of clear anatomical landmarks in the distal esophagus. The disease extent is, therefore, determined by endoscopy or endoscopic ultrasound (EUS). Currently, there is limited knowledge of the microscopic disease extent beyond the endoscopy findings. Soft-tissue contrast is poor on both CT and EUS. Furthermore, EUS is prone to overstaging due to the inability to distinguish inflammatory changes from tumor infiltration 2 and understaging because of limited EUS resolution. [3] [4] [5] The extent of microscopic tumor invasion is, therefore, uncertain at the time of RT planning. This uncertainty leads to the use of very large clinical target volume (CTV) margins to ensure tumor coverage.
Optical coherence tomography (OCT) is a minimally invasive and high-resolution (10-30 lm) imaging technique that obtains cross-sectional images of tissue based on the backscattering of light. OCT is similar to ultrasound, however, it uses near infrared light instead of sound. 6, 7 While the resolution of OCT is around 10 times higher than that of ultrasound, 8 it suffers from limited depth of penetration in the range of up to 3.0 mm. 9 This limitation is due to light scattering and absorption in tissue. OCT has potential for guiding diagnosis and treatment of esophageal cancer, because inflatable cylindrical probes exist that are able to scan the esophageal wall in 3-D using a single rotating optical fiber that is retracted through the esophagus. A probe-based OCT system facilitates in vivo OCT imaging alongside standard endoscopy for minimally invasive diagnosis. 10, 11 Previous studies showed the effectiveness of OCT to identify structures including esophageal wall layers down to the muscular propria, [12] [13] [14] "pit and gland" morphology, and glandular structure on a microscopic level. 15, 16 OCT is, therefore, a promising imaging modality to improve knowledge of the disease extent beyond EUS findings.
An accurate translation of the disease extent that is visible on EUS imaging to the CT scan used for RT planning remains a challenging task. Fiducial markers are often used to facilitate the transfer process. Such fiducial markers are also used for setup verification prior to radiation dose delivery that is mostly conducted using cone-beam CT in imageguided RT. Fiducial markers have been successfully applied in a variety of treatment sites to provide guidance. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Endoscopy-/EUS-guided implantation of fiducial markers has recently been shown feasible in esophageal cancer patients. 26, 28 These fiducial markers may also allow translation of the OCT findings to the CT images used for RT planning, therefore their visibility in OCT images needs to be verified.
Currently, various commercially solid and liquid fiducial markers are available to guide RT. Solid fiducial markers are usually made of gold and are well visible in CT images but implantation typically requires separate load actions/needle retractions per marker. Liquid markers on the other hand are faster to insert as a needle is loaded once and then used for multiple injections.
In this study, we investigated the visibility with OCT of both solid and liquid commercially available fiducial markers at various depths using a set of dedicatedly manufactured esophageal phantoms. Visibility of the fiducial markers on OCT and CT will facilitate registration of these imaging modalities. Therefore, in addition, we retrospectively evaluated how often in the current clinical practice esophageal fiducial markers are inserted in the OCT visualization range.
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MATERIALS AND METHODS

2.A. Materials phantom study
2.A.1. Esophageal phantom design
We designed and fabricated a set of silicone elastomerbased esophageal phantoms consisting of three layers with negligible absorption and homogeneous scattering properties achieved using different TiO 2 concentrations. The phantoms represent the normal human esophageal wall layers (Fig. 1) . We improved a previous method for fabricating optical phantoms with controlled optical properties 29 by adding curing agent (silicone elastomer curing agent of the Sylgard 184) to better disperse the TiO 2 particles in the mixing procedure during phantom fabrication.
We designed a flat phantom instead of a tubular structure resembling the normal human esophagus for the sake of simplicity (Fig. 2) . The thicknesses of the esophageal phantom layers match the histology of ex vivo OCT images of a healthy esophagus. 12 Ideally, we would represent all esophageal anatomical wall layers (epithelium, lamina propria, muscular mucosa, submucosa, and muscularis propria) in the phantoms. However, we integrated the lamina propria, muscular mucosa, and submucosa in a single layer because of the small difference in scattering properties and technical difficulties to produce layers thinner than 0.5 mm. Thus, our esophageal phantoms include three layers, in which the first layer represents epithelium, the second layer represents lamina propria, muscular mucosa, and submucosa, and the third layer represents muscularis propria (Fig. 1) .
We chose an attenuation coefficient of 1.0 mm À1 for the first layer corresponding to an epithelium with a thickness of 0.5 mm, an attenuation coefficient of 2.0 mm À1 for the combined lamina propria, muscular mucosa, and submucosa layers with a thickness of 0.6 mm, and an attenuation coefficient of about 0.2 mm À1 for the third phantom layer resembling the esophageal muscularis propria, to mimic the very low attenuation coefficient of the muscularis propria. The thickness of this layer was about 6-8 mm. We chose attenuation coefficients based on our first in vivo esophageal OCT data at the time of fabricating the phantoms.
2.A.2. Fiducial markers
We included eight types of commercially available fiducial markers in our study (Table I) . We investigated both solid fiducial markers, with different diameters, and liquid fiducial markers. In total, nine solid fiducial markers were placed at four depths (0.5, 1.1, 2.0, 3.0 mm) and four liquid fiducial markers at three depths (1.1, 2.0, 3.0 mm). In order to precisely control their position, the fiducial markers were placed in the phantom using forceps or syringes for solid and liquid fiducial markers, respectively, during the phantom fabrication. Therefore, each layer was poured and cured before proceeding to the next layer. The solid fiducial markers were placed when layers were half cured to ensure that the fiducial markers maintain their position. Special treatment was needed for one of the liquid markers. BioXmark (Nanovi, Lyngby, Denmark) is a sugar-based fiducial marker that was tested in both liquid and gel states. The liquid state is achieved by using the marker right after opening the ampoule. When the BioXmark is injected into a living tissue it turns over time into a gel, therefore also the gel state was tested. For this purpose, the solution was injected into water and kept there for 24 hr so that the alcohol vaporized and the material became a sticky substance and achieved a higher viscosity. Subsequently, we implanted the BioXmark fiducial markers by taking the material out of the water using a stirring rod. Such a procedure was not required for the other liquid fiducial markers which have a stable chemical composition. Figures 3 and 4 show the step by step fabricating process of esophageal phantoms containing solid and liquid fiducial markers, respectively. The esophageal fabricating recipe is provided in the supplementary materials section.
2.B. Retrospective patient study
Endoscopy-/EUS-guided radiopaque fiducial marker implantation improves translation of the tumor extent on endoscopy/EUS to the so-called RT planning CT in patients with esophageal cancer. 26 The procedure is performed under conscious sedation with midazolam or under propofol-based sedation with monitored anesthesia care. In a feasibility study, fiducial markers were implanted in the upper and lower boundaries and the center of the tumor in the submucosal layer of 30 patients. 28, 30 Here we only analyze the markers at the upper and lower boundaries of the tumor, as these are representative for our ultimate aim, which is to disclose the extent of microscopic disease. The marker feasibility study 28 was performed with our medical ethical board committee approval. Written informed consent forms were provided to and signed by the patients.
In the planning CT scans, we retrospectively measured the distance between the fiducial markers and the inner wall of the esophagus using RadiAnt DICOM Viewer software (Medixant, Poznan, Poland). We measured the distance from the inner esophageal wall to both the nearest border and the center of the fiducial markers. Of a total of 91 fiducial markers visible on CT in 30 patients, 26 markers were implanted at the tumor boundaries, and only 19 markers from 16 patients were eligible for our study. This was because of poor visibility or absence of the esophageal lumen at the same CT slice that included the fiducial markers. Moreover, the strong signal of some fiducial markers obscured the esophageal lumen because of ending in the epithelium layers instead of the submucosal layer. Fiducial markers that were used in these 16 patients are: solid gold (Cook Medical, Limerick, Ireland) in three patients, solid gold (in-house manufactured) in three patients, Visicoil (IBA Dosimetry, Bartlett, TN, USA) in seven patients, and Hydrogel (TracelT Hydrogel, Augmenix Inc., Walthman, MA, USA) in three patients.
2.C. Imaging equipment
We scanned the esophageal phantoms with a first-generation endoscopic OCT imaging system (Nvision VLE (volumetric laser endomicroscopy) Imaging System, NinePoint Medical Inc., Cambridge, MA, USA), and a CT scanner (LightSpeed RT 16 CT, General Electric Company, Waukesha, WI, USA).
The balloon-centered rotating probe of the OCT imaging system is capable of generating 3-D images over a 60 mm segment length of the esophageal wall's mucosa and submucosa 31 up to a depth of 3.0 mm with 7 lm resolution using near infrared light. The scanner uses a rapid wavelength swept light source, enabling interference signal quantification as a function of wavelength; it records depth-resolved TABLE I. Overview of the investigated fiducial markers with corresponding length, diameter, volume (for the liquid markers solely the volume is given), averaged mean intensity from fiducial marker ROIs of 0.6 9 0.6 mm at all depths (MI Marker ), averaged mean intensity from background ROIs of 0.6 9 0.6 mm at all depth (MI Background ), averaged standard deviation of the background intensity ROIs of 0.6 9 0.6 mm at all depths (SDðI Background )), and contrast-to-backgroundnoise ratio (CNR). reflectivity profiles for every scan position to create 3-D OCT images. 7, 31, 32 A polymer-based noncompliant balloon (25 mm in diameter) opens the esophageal lumen in patients and centralizes the probe to generate symmetric 3-D volume images. The probe undergoes 1200 rotations over its length using an automatic pullback of the rotating optical probe, which takes approximately 90 s. 31, 33 The recorded scans consist of 1200 9 1024 9 4096 voxels.
We used the CT scanner to image patients -as a part of standard planning for RT -as well as the esophageal phantoms. For the phantoms, we set both the axial slice thickness and the interval between slices to 1.25 mm. Each slice consists of 512 9 512 pixels, with a pixel size of 1.0 9 1.0 mm. For the patients, the axial slice thickness and interval was set to 2.5 mm, with a pixel size of 1.0 9 1.0 mm.
2.D. Methods
2.D.1. Phantom study
To investigate the visibility of fiducial markers at different depths on OCT, we scanned all the esophageal phantoms using the OCT system. OCT imaging started with connecting the catheter containing a single rotating optical probe to the rotary junction of the system. We then calibrated the system, followed by inflating the balloon to the recommended pressure of 5 psi to full expansion. We placed the probe on the flat surface of the phantom by hand (Fig. 2) at the location of the fiducial markers. We verified our fabricated layer thicknesses using the ruler measurement of the system interface on OCT. We used the same resolution setting for imaging all of the fiducial markers at all depths.
The visibility of each fiducial marker was investigated by visually inspecting the 3-D images individually. In addition, we evaluated the visibility of the fiducial markers at each depth quantitatively. We calculated the contrast-to-background-noise ratio (CNR) for each fiducial marker as follows:
where MI Marker is the mean intensity from fiducial marker region of interest (ROI) of 0.6 9 0.6 mm, the ROI was located at the top surface of the marker; MI Background is the mean intensity from background ROI of 0.6 9 0.6 mm at the corresponding marker depth; and SDðBackgroundÞ is defined as the standard deviation of the background intensities within the ROI of 0.6 9 0.6 mm.
To report a CNR value for each of the 13 investigated markers separately, we averaged MI Marker , MI Background , and SDðI Background Þ at all depths, and next calculated the CNR from the averages (MI Marker ; MI Background ; and SDðI Background )). To report a single CNR per depth, we used the same procedure, averaging MI Marker , MI Background , and SDð I Background Þ over all solid fiducial markers at the same depth, and all liquid fiducial markers at the same depth. We tested the feasibility of OCT/CT rigid registration for an esophageal phantom with PolyMark fiducial markers. We reconstructed each OCT volume image from 1200 cross-sectional B-scan images and each CT volume image from 480 CT slices using the AMIRA software (AMIRA, Mercury Computer Systems, Berlin, Germany). Next, we manually overlapped two corresponding fiducial markers in OCT and CT images based on their center and outer borders, insofar visible. This enabled manual rigid registration between OCT and CT using the fiducial markers as a reference in AMIRA. To obtain an indication of the expected minimum inaccuracy associated with rigid registration between OCT and CT, we compared the actual fiducial marker sizes (1.0 mm diameter, 3.0 mm length) with their appearances on both CT and OCT. We also measured the lateral distance between the borders of the fiducial markers in both OCT and CT images and compared our findings with the actual lateral distance in the esophageal phantom 
2.D.2. Retrospective patient study
In the retrospective patient study, we measured the distance from the inner esophageal wall to both the nearest border and center of the fiducial markers. The identification of the esophageal lumen and the location of the fiducial marker were confirmed by a physicist and an experienced esophageal cancer radiation oncologist. Figure 5 shows images of all solid markers, where Fig. 5(a) (Visicoil marker, 0 .75 mm in diameter at 0.5 mm depth) is annotated with information about the phantom layers. The three layers in the phantom could be easily differentiated in the OCT images. The TiO 2 particles were homogenously distributed over each layer. Depth measurements on OCT indicated agreement between the intended and fabricated layer thicknesses with an average of 0.53 AE 0.08 mm and 0.65 AE 0.13 mm for the first and the second layers, respectively. Figures 5 and 6 illustrate that all types of fiducial markers are visible on OCT at all tested depths; with good visibility even for the deepest ones. The gold fiducial markers had better visibility in OCT images compared to nongold markers, which can be attributed to the high backscattering coefficient of gold. Larger markers were considerably easier to visualize. All the liquid fiducial markers were visible on OCT; however, Hydrogel gave slightly better results compared to BioXmark and Lipiodol. Liquid fiducial markers are less visible than the solid fiducial markers because of smaller scattering differences with the phantom layers (Fig. 6 ). Both solid and liquid fiducial markers are easier to visualize and identify in 3-D OCT images compared to single cross-sectional images. Table I shows the CNRs of all fiducial markers within the ROIs. In terms of CNR, the Visicoil and BioXmark were the most and least visible fiducial markers on OCT, respectively. Overall, the CNR was 1.74-fold higher for the solid fiducial markers than the liquid fiducial markers. Hence, overall solid fiducial markers are better visible than liquid fiducial markers. Hydrogel has slightly higher CNR than QLRAD solid gold and one of the Gold Anchor markers (size: 0.28 mm in diameter). The average CNR of the solid fiducial markers at Manual rigid registration between OCT and CT based on two fiducial markers from a phantom with solid fiducial markers was feasible (Fig. 8) , here using PolyMark fiducial markers (1.0 mm in diameter and 3.0 mm long) at depths of 0.5 and 1.1 mm. Our OCT measurements confirmed the 1.0 mm diameter size for both PolyMark fiducial markers and the 21.0 mm lateral distance between them. The measured lengths determined from a single B-scan were 3.3 and 2.3 mm which are different from the actual length of 3.0 mm. If the OCT B-scan is not longitudinally aligned with a fiducial marker, part of the fiducial marker will be missed in the image, leading to a shorter measured length. Our CT measurements determined diameters of 2.1 and 2.7 mm with 3.3 mm lengths for both PolyMark fiducial markers. The distance between the borders of the two PolyMark fiducial markers was 20.0 mm on CT. Measurements did not show noticeable size differences of any of the markers as function of depth. On CT, the fiducial markers appeared larger and bulkier because of artifacts. However, the size of the fiducial markers is not clinically important, as long as their centroid can be accurately determined.
RESULTS
3.A. Phantom study
3.B. Retrospective patient study
The mean closest distance of the 19 fiducial markers from the border to the esophageal inner wall was 1.6 mm (range: 0.0-5.6 mm); the median was 0.7 mm. The mean distance from the center of the fiducial markers to the esophageal inner wall was 3.6 mm (range: 1.5-7.0 mm); the median was 2.8 mm. Taking a 3.0 mm cut-off value, 84% of the markers will be partly visible (distance from the nearest border of the marker to the esophageal inner wall) and the center of the marker will be visible for 53% of the markers (distance from the center of the marker to the esophageal inner wall). These fiducial markers could be used as landmarks for OCT and CT registration.
DISCUSSION
In this study, we investigated the visibility of both solid and liquid commercial fiducial markers on OCT for esophageal cancer RT using dedicated esophageal phantoms. We demonstrated the visibility of (Visicoil, Gold Anchor, Flexicoil, PolyMark, QLRAD Solid Gold, BioXmark, Lipiodol, and Hydrogel) fiducial markers on OCT. It thus allows adopting these fiducial markers as the primary guidance during tumor delineation integrating OCT with CT. For this study, we first successfully built a set of custom phantoms. The esophageal phantoms have layer thicknesses and scattering contrasts similar to a normal human esophagus. Our retrospective esophageal marker patient data analysis verified that most of the implanted fiducial markers in current clinical practice are in the visualization depth range of the OCT. Our results also demonstrated that all the fiducial markers were visible on OCT at all investigated depths. Solid fiducial markers showed better visibility on OCT, with on average a 1.74-fold better contrast. Fiducial markers are therefore promising to translate OCT findings to the RT planning CT as well as for registration with other imaging modalities. Our results warrant further studies on the potential of OCT to guide tumor delineation through fiducial marker implantation and this last part further enables the use of fiducial markers as a reference for OCT to CT registration. Although we could easily identify all fiducial markers in our esophageal phantoms and in ex vivo experiments, we need in vivo clinical studies to test localization sensitivity in esophageal tissue, which may be hampered by surrounding tissue.
Our proposed phantom protocol and materials are useful to resemble other anatomical structure as well and may, therefore, have wider application in other research fields. Because of technical difficulties we could not create layers thinner than 0.5 mm. Thus, we integrated the lamina propria, muscular mucosa, and submucosa in a single layer. We do not expect any changes in the results by mimicking all esophageal layers, because of very similar scattering properties between these layers. We improved the previously reported phantom protocol 29 for creating thin layers in a more accurate fashion and maintained more control over the scattering and absorption spectra of the esophageal phantoms. The two-compound silicone matrix material of the esophageal phantom can be made with different mechanical properties by changing the component ratios. Therefore, silicone-based phantoms may also be used for elastography applications. 34 Besides, the silicone-based phantoms are long-lasting and easy to transport. 29 Visicoil, solid gold, Hydrogel, and metal clip fiducial markers were applied and tested in esophageal cancer patients in other studies to date. [24] [25] [26] 28, 30 Hydrogel fiducial markers are also reported for esophageal cancer RT and its visibility was demonstrated on different imaging modalities such as magnetic resonance imaging (MRI), ultrasound, cone-beam CT, and CT. 28, 35 Fiducial gold markers are preferred compared to Hydrogel for esophageal cancer because of their stability and continuous level of visibility on cone-beam CT. 28 Although Hydrogel is well visible on CT, it is resorbed into the tissue over the treatment course by about 80% after AE13 days. 28 Hence, the visibility of the Hydrogel fiducial marker worsens over time. Solid gold markers are prone to detach more easily than the Visicoil coil-shaped and Gold Anchor markers. 28 Lipiodol fiducial markers are frequently used in bladder cancer RT, 17, [36] [37] [38] [39] although they are prone to extravasation into surrounding tissues. Other studies reported on the use of Lipiodol in lung cancer, 40 prostate cancer, 41 and esophageal cancer RT. 17, [36] [37] [38] [42] [43] [44] The visibility of various fiducial markers on CT, cone-beam CT, and MRI has been reported. 30, 45 Fiducial markers not only assure defining the upper and lower boundaries of a tumor on the planning CT but also are potentially useful for multimodal image registration such as between CT and OCT.
We quantitatively measured the CNR of all fiducial markers at different depths. More pronounced but difficult to capture in a quantitative metric is the visual appearance of the fiducial marker in an OCT image. Strong contrast is generated by the strong backscatter from the marker, and the subsequent shadowing, or lack of signal below the marker.
OCT, in general, provides more details compared to EUS because of its higher resolution. This can overcome the understaging of the disease extent that is known in EUS. 46 There are also reports on using OCT for early detection of neoplastic lesions such as intramucosal cancer in Barrett's esophagus patients 33 and to detect subsquamous glandular structures. 47 OCT is, however, not able to differentiate between inflammation and tumor infiltration. 5 EUS is uncertain to determine the extent of microscopic tumor invasion in the esophagus. For RT planning, the gross tumor volume (GTV) is therefore typically extended to account for the subclinical disease spread which can currently not be fully imaged. Moreover, there are uncertainties in treatment planning and delivery, caused by, e.g., esophageal movement during irradiation, which lead to the need for safety margins around the CTV to create the so-called planning target volume (PTV). 1 The recommended safety margins based on EUS and PET/CT to apply around the GTV in order to create the CTV is 3 cm in cranial-caudal direction with 1 cm around the pathological lymph nodes. 48, 49 Hypothetically, the high resolution of OCT determines the tumor extent better, which will lead to expanding the GTV and improve the focus of -or may shrink the CTV. The PTV margins remain unchanged. Yet, understanding the full potential of OCT requires clinical studies. Figure 1 illustrates that we slightly underestimated the scattering properties of the healthy esophageal wall when fabricating our esophageal phantoms. However, ex vivo OCT experiments demonstrated the visibility of implanted Visicoil (0.35 mm diameter, 10.0 mm length) and Hydrogel (0.4 ml) fiducial markers in the human proximal esophagus (healthy part) after esophagectomy (Fig. 9) . Previous studies on optical properties of the esophagus are based on diffuse reflectance spectroscopy, 50, 51 which is different from OCT which measures the attenuation coefficient. To our understanding, there are no studies reporting on the attenuation coefficient of the healthy human esophagus and esophageal layers.
The findings of this study are not limited to esophageal cancer, however, specific types of fiducial markers might be preferable depending on the tumor site. We think that our OCT findings can be translated to other sites of the body because of the expected consistent OCT scattering properties discrepancies of the different endothelial tissues and the investigated fiducial markers. However, OCT imaging is limited by the probe availability for the diversity of hollow body organs and the amount of useful information in the visualization range of the OCT for specific parts of the body.
Based on the retrospective esophageal cancer patient data analysis, we found that in current clinical practice at our hospital 84% of the markers are implanted at a depth within 3.0 mm, which is likely to be in the OCT visualization range even though the marker placement protocol was not designed with OCT in mind. An adapted endoscopy-/EUS-guided fiducial marker placement protocol may help to bring this percentage closer to 100%. An inflated balloon of the probe could stretch the esophageal wall slightly, which could result in a decrease of the distance between the fiducial markers and the lumen.
CONCLUSIONS
In conclusion, we studied the visibility of 13 solid and liquid commercially available fiducial markers with various diameters and state of matter at different depths on OCT. For this purpose, we designed and fabricated a set of dedicated esophageal phantoms enabling a controlled environment for our investigation. The results indicate that all the investigated fiducial markers are visible on OCT at depths ≤3.0 mm with superior visibility for solid fiducial markers compared to the investigated liquid fiducial markers. Hydrogel is slightly better visible than the other investigated liquid fiducial markers. Based on the retrospective patient study we can conclude that the majority of the markers in current clinical practice are placed within the OCT visualization range, enabling the use of fiducial markers as the reference for OCT and CT registration. This also facilitates studies on the use of OCT to identify longitudinal tumor extension and guide marker implementation to improve RT planning.
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